Compare NKX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | ALT |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 573.8M |
| IPO Year | N/A | 2005 |
| Metric | NKX | ALT |
|---|---|---|
| Price | $11.70 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 146.4K | ★ 4.0M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $11.68 | $2.56 |
| 52 Week High | $13.20 | $6.44 |
| Indicator | NKX | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 25.22 | 57.93 |
| Support Level | N/A | $3.18 |
| Resistance Level | $12.49 | $3.32 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 12.28 | 56.68 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.